Oncology Training | Alebat Education

PARP inhibitors in metastatic prostate cancer in non-castrated patients

Trastuzumab-Deruxtecan and Pertuzumab as First-Line Treatment for HER2-Positive Metastatic Breast Cancer

Localized Bladder Cancer: Perioperative Treatment in Patients Who Are Not Eligible for Cisplatin

TKI After I0 in Renal Cell Carcinoma: FlIR Study—Lenvatinib and Everolimus vs. Cabozantinib

Perioperative Management in the Early Stages of Lung Cancer

Pembrolizumab and Axitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma

NIAGARA Study: Perioperative Chemotherapy and Immunotherapy for Localized Bladder Cancer.

Combination of targeted therapies in advanced non-small-cell lung cancer with an EGFR mutation

Belzutifan in Metastatic Renal Cell Carcinoma

Trastuzumab Deruxtecan in HER2-low and ultra-low metastatic breast cancer

Individualized Treatment of Metastatic Renal Cell Carcinoma

Update on Enfortumab Vedotin and Pembrolizumab in Metastatic Urothelial Cancer

Talazoparib in Castration-Resistant Prostate Cancer

Update on Treatment with 177Lu-PSMA-617 in CPRC

Non-clear-cell renal cell carcinoma: SWOG S1500 Study

Improved Survival with Adjuvant Therapy for Kidney Cancer

Metastatic hormone-sensitive prostate cancer. Which patients benefit from docetaxel?

First-Line Cisplatin-Free Chemotherapy and Immunotherapy for Metastatic Urothelial Carcinoma: A Paradigm Shift?

First-line combination of chemotherapy and immunotherapy in metastatic urothelial carcinoma

Treatment of metastatic urothelial carcinoma following chemotherapy and immunotherapy.

First-line triple therapy in patients with metastatic hormone-sensitive prostate cancer.

Adjuvant immunotherapy for invasive urothelial carcinoma.

Teragnosis in prostate cancer.

Triple therapy for CaPHSM1.

Maintenance therapy with avelumab in metastatic urothelial carcinoma.

Adjuvant Treatment for Renal Cell Carcinoma.

Local radiation therapy for low-volume, hormone-sensitive metastatic prostate cancer.

Bladder-sparing treatment in muscle-invasive urothelial carcinoma.

Erdafitinib in metastatic urothelial carcinoma

Treatment of biochemical relapse.

Dostarlimab as first-line therapy for advanced endometrial carcinoma

Niraparib as maintenance therapy following first-line treatment for advanced ovarian cancer

🔴 October 21 | 4:30 p.m.